CROMSOURCE, an international CRO providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced the appointment of its new Chief Medical Officer Dr. Grzegorz Rychlik, and the expansion of its Medical Affairs Services department.

Dr. Rychlik has more than 26 years of experience in the pharmaceutical industry. He has held positions of increasing responsibility with sponsor and service companies of various sizes, including large, global organizations such as Pfizer, Novartis and Parexel, as well as virtual, small and mid-sized enterprises. Dr. Rychlik's most recent position was managing director with MRCD Pharma Services in the United Kingdom, and prior to that he served as medical director and chief medical officer for various organizations. His therapeutic expertise is closely aligned with CROMSOURCE's key areas of focus and expertise, namely oncology, ophthalmology, respiratory, cardiovascular, CNS and medical devices.

"The addition of an experienced and respected medical professional such as Greg strongly positions CROMSOURCEto be able to further support the increasingly complex product development needs of our clients. Additionally, as we expand our Medical Affairs offering we will optimize and grow our consultancy and medical services to better serveour clients," stated Dr. Oriana Zerbini, founder and chief executive officer of CROMSOURCE.

Dr. Troy McCall, CROMSOURCE chief operating officer, added, "We are very pleased to have Dr. Rychlik join the CROMSOURCE team. Under his leadership, CROMSOURCE will expand our medical monitoring, pharmacovigilance, and medical writing services to meet growing client needs. Having highly experienced and skilled individuals such as Greg within the Medical Affairs Services group will allow for the optimization and standardization of interdependent processes, while leveraging efficiencies and ensuring that the highest level of quality is delivered."